Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
D.T. Wai Meng
Institution:
National Cancer Centre Singapore
Observed institution:
National Cancer Centre Singapore
OpenAlex ID:
A5083828324
LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
2022
·
A. Hollebecque
, M. Borad
, et al.
·
Annals of Oncology
·
44
76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
2022
·
J.O. Park
, D.T. Wai Meng
, et al.
·
Annals of Oncology
·
9
Show more works
View as search
Works count:
2
Citation count:
53
H-index:
2
I10-index:
1
Year
Topic
Type